Visit our secure online portal to start your order.
AmbryPort Login or Create an AccountConfidently guiding patient care through reliable results
Finding answers through superior variant interpretation
Understanding human disease through innovation, research, and partnerships
Offering anonymous, no-cost genetic testing and confidential genetic counseling to patients suspected of having or clinically diagnosed with hATTR amyloidosis through the hATTR Compass program
Choose an option below to order
your kit and start your genetic testing
Will insurance cover my patient's genetic test?
Click HereWhy partner with us?
Learn MoreWe are driven to give healthcare providers the most advanced testing information available so you can determine the best treatment options for your patients.
We now offer single site analysis (SSA) at no additional cost to family members
following single gene or panel testing* of the first family member (proband) within 90 days of the original Ambry report date.
Order Now*excludes Secondary Findings and SNP Array tests
Amyloid deposits found in biopsy specimens, in combination with identification of a pathogenic variant in TTR, are necessary to establish the diagnosis.1 Genetic testing is useful for diagnostic confirmation in symptomatic individuals and for testing of at-risk asymptomatic family members (including prenatal diagnosis). Molecular confirmation of a diagnosis may help avoid unnecessary testing and procedures, guide recommendations for medical treatment and screening, and offer accurate genetic counseling (including risk assessment) for a family.
Genetic testing may be considered for any of the following:
Our familial TTR amyloidosis genetic testing can detect >99% of affected individuals (clinical sensitivity) and can detect >99.9% of described sequencing mutations, when present (analytic sensitivity).
Our familial TTR amyloidosis genetic testing includes next generation sequencing (NGS) and deletion/duplication analysis of the TTR gene. Genomic deoxyribonucleic acid (gDNA) is isolated from the patient’s specimen using a standardized kit and quantified. Sequence enrichment of the targeted coding exons and adjacent intronic nucleotides is carried out by a bait-capture methodology using long biotinylated oligonucleotide probes, followed by polymerase chain reaction (PCR) and NGS.
Sanger sequencing is performed for any regions missing, or with insufficient read depth coverage for reliable heterozygous variant detection. Reportable small insertions and deletions, potentially homozygous variants, variants in regions complicated by pseudogene interference, and single nucleotide variant calls not satisfying 100x depth of coverage and 40% het ratio thresholds are verified by Sanger sequencing.2 This assay targets all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. Gross deletion/duplication analysis is performed utilizing a targeted chromosomal microarray.
HGVS | HUGO Gene Name | Disease |
m.583G>A | MT-TF | MELAS / MM & EXIT |
m.1494C>T | MT-RNR1 | DEAF |
m.1555A>G | MT-RNR1 | DEAF |
m.1606G>A | MT-TV | AMDF |
m.1644G>A | MT-TV | HCM+MELAS |
m.3243A>G | MT-TL1 | MELAS / LS/DMDF / MIDD / SNHL / FSGS / CPEO |
m.3251A>G | MT-TL1 | MELAS |
m.3252A>G | MT-TL1 | MELAS |
m.3256C>T | MT-TL1 | MELAS |
m.3260A>G | MT-TL1 | MMC |
m.3271T>C | MT-TL1 | MELAS |
m.3291T>C | MT-TL1 | MELAS / Myopathy / Deafness+Cognitive Impairment |
m.3302A>G | MT-TL1 | MM |
m.3303C>T | MT-TL1 | MMC |
m.3460G>A | MT-ND1 | LHON |
m.3635G>A | MT-ND1 | LHON |
m.3697G>A | MT-ND1 | MELAS/LS/LDYT |
m.3700G>A | MT-ND1 | LHON |
m.3733G>A | MT-ND1 | LHON |
m.3890G>A | MT-ND1 | Progressive encephalomyopathy / LS / optic atrophy |
m.4171C>A | MT-ND1 | LHON |
m.4269A>G | MT-TI | FICP |
m.4274T>C | MT-TI | CPEO/Motor Neuron Disease |
m.4298G>A | MT-TI | CPEO / MS |
m.4300A>G | MT-TI | MICM |
m.4308G>A | MT-TI | CPEO |
m.4332G>A | MT-TQ | Encephalopathy / MELAS |
m.5537_5538insT | MT-TW | Leigh Syndrome |
m.5650G>A | MT-TA | Myopathy |
m.5703G>A | MT-TN | CPEO/MM |
m.7222A>G | MT-CO1 | peripheral neuropathy, muscle weakness, ptosis, abnormal muscle pathology |
m.7445A>G | MT-TS1 | SNHL |
m.7471dupC | MT-TS1 | PEM/AMDF/Motor neuron disease-like |
m.7497G>A | MT-TS1 | MM / EXIT |
m.7511T>C | MT-TS1 | SNHL |
m.8344A>G | MT-TK | MERRF |
m.8356T>C | MT-TK | MERRF |
m.8363G>A | MT-TK | MICM+DEAF/ MERRF/ Autism/ LS/ Ataxia+Lipomas |
m.8969G>A | MT-ATP6 | Mitochondrial Myopathy, Lactic Acidosis, |
m.8993T>C | MT-ATP6 | NARP/Leigh Disease/MILS/other |
m.8993T>G | MT-ATP6 | NARP/Leigh Disease/MILS/other |
m.9176T>C | MT-ATP6 | FBSN/Leigh Disease |
m.9176T>G | MT-ATP6 | Leigh Disease/Spastic Paraplegia |
m.9185T>C | MT-ATP6 | Leigh Disease/Ataxia/NARP-like disease |
m.10010T>C | MT-TG | PEM |
m.10158T>C | MT-ND3 | Leigh Disease |
m.10191 T>C | MT-ND3 | Leigh Disease/Leigh-like Disease/ESOC |
m.10197G>A | MT-ND3 | Leigh Disease/Dystonia/Stroke/LDYT |
m.10663T>C | MT-ND4L | LHON |
m.11777C>A | MT-ND4 | Leigh Disease |
m.11778G>A | MT-ND4 | LHON, Progressive Dystonia |
m.12147G>A | MT-TH | MERRF-MELAS/Enchephalopathy |
m.12258C>A | MT-TS2 | DMDF / RP+SNHL |
m.12315G>A | MT-TL2 | CPEO/KSS |
m.12320A>G | MT-TL2 | Myopatrhy |
m.12706T>C | MT-ND5 | Leigh Disease |
m.13513G>A | MT-ND5 | Leigh Disease/MELAS/LHON-MELAS Overlap Syndrome |
m.13514A>G | MT-ND5 | Leigh Disease/MELAS |
m.14459G>A | MT-ND6 | LDYT/Leigh Disease |
m.14482C>G | MT-ND6 | LHON |
m.14484T>C | MT-ND6 | LHON |
m.14487T>C | MT-ND6 | Dystonia/Leigh Disease/Ataxia |
m.14495A>G | MT-ND6 | LHON |
m.14568C<T | MT-ND6 | LHON |
m.14674T>C | MT-TE | Reversible COX deficiency myopathy |
m.14709T>C | MT-TE | MM+DMDF / Encephalomyopathy |
m.14849T>C | MT-CYB | EXIT / Septo-Optic Dysplasia |
m.15579A>G | MT-CYB | Multisystem Disorder, EXIT |